Trials / Unknown
UnknownNCT02380235
Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children (Clinical Trial I)
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 600 (estimated)
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 3 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the safety and efficiency of Pegylated Somatropin (PEG Somatropin) Injection in the treatment of endogenous growth hormone deficiency (GHD) in the broad of population of children.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PEG-somatropin | 0.20mg/kg/w |
| BIOLOGICAL | PEG-somatropin | 0.12mg/kg/w |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2017-06-01
- Completion
- 2017-07-01
- First posted
- 2015-03-05
- Last updated
- 2017-06-16
Locations
12 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02380235. Inclusion in this directory is not an endorsement.